Skip to main content
SpringerLink
Log in

Alzheimer’s disease: cost containment is awaiting drug development

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Max W. The cost of Alzheimer’s disease: will drug treatment ease the burden? PharmacoEconomics 1996 Jan; 9(1): 5–10

    Article  PubMed  CAS  Google Scholar 

  2. Huang L, Cartwright W, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988; 103: 3–7

    PubMed  CAS  Google Scholar 

  3. Hermann CK. Dementia: a costly problem. PharmacoEconomics 1992 Dec; 2(6): 444–8

    Article  PubMed  CAS  Google Scholar 

  4. Gray A, Renn P. Alzheimer’s disease: the burden of the illness in England. Health Trends 1993; 25(1): 31–7

    PubMed  CAS  Google Scholar 

  5. Evans D. Estimated prevalence of Alzheimer’s disease in the United States. Milbank Q 1990; 68: 267–89

    Article  PubMed  CAS  Google Scholar 

  6. Five-year delay of Alzheimer’s onset would save an estimated %50 bil. annually, aging report says. FDC Reports — Blue Sheet 1995 May 3: 4–6

    Google Scholar 

  7. Tacrine offers modest benefits in some patients with Alzheimer’s disease. Drug Ther Perspect 1994 Dec 12; 4(12): 1–4

    Article  Google Scholar 

  8. Holford NHG, Peace K. The effect of tacrine and lecithin in Alzheimer’s disease: a population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 1994; 47(1): 17–23

    PubMed  CAS  Google Scholar 

  9. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week, randomized, controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  10. Lyketsos CG, Corazzini K, Steele CD, et al. Guidelines for the use of tacrine in Alzheimer’s disease: clinical application and effectiveness. J Neuropsychiatry Clin Neurosci 1996; 8(1): 67–73

    PubMed  CAS  Google Scholar 

  11. Schneider LS, Farlow MR. Predicting response to cholinesterase inhibitors in Alzheimer’s disease. CNS Drugs 1995 Aug; 4(2): 114–24

    Article  CAS  Google Scholar 

  12. Balson R, Gibson PR, Ames D, et al. Tacrine-induced hepatotoxicity: tolability and management. CNS Drugs 1995 Sep; 4(3): 168–81

    Article  CAS  Google Scholar 

  13. MacPherson S. Galanthamine: the new treatment of choice in Alzheimer’s disease? Inpharma 1995 Sep 2; (1002): 3–5

  14. Corey-Bloom J, Galasko D. Adjunctive therapy in patients with Alzheimer’s disease. Drug Aging 1995 Aug; 7(2): 79–87

    Article  CAS  Google Scholar 

  15. Volicer L, Collard A, Hurley A, et al. Impact of special care unit for patients with advanced Alzheimer’s disease on patients’ discomfort and costs. J Am Geriatr Soc 1994 Jun; 42: 597–603

    PubMed  CAS  Google Scholar 

  16. White H, Clipp EC, Hanlon JT, et al. The role of the caregiver in the drug treatment of dementia. CNS Drugs 1996 Jul; 4(1): 58–67

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alzheimer’s disease: cost containment is awaiting drug development. Drugs Ther. Perspect 7, 13–16 (1996). https://doi.org/10.2165/00042310-199607090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607090-00005

Search

Navigation